Pioneering the next generation of pulmonary medicine and microbiome science
Changes in microbial signatures of the lungs and airways are associated with worsening chronic respiratory disease and persistent inflammation. As such, Alveolus Bio is focused on harnessing the anti-inflammatory power of commensal bacteria strains and their byproducts for inhaled delivery straight to the target tissue: the lungs.
Origin Story
Alveolus Bio began in Dr. Vivek Lal’s Pulmonary Microbiome Lab and Dr. Amit Gaggar’s Program in Lung Protease and Matrix Biology at the University of Alabama at Birmingham (UAB).
The collaborating scientists published groundbreaking research on the neonatal lung microbiome, and became one of the first to conduct gain and loss of function studies on underlying mechanisms of neutraphillic inflammation and the extracellular matrix of the lung.
Scientific Team
Alveolus Bio’s scientific team and advisors have expertise across a spectrum of chronic respiratory diseases from Bronchopulmonary Dysplasia, to Cystic Fibrosis, to Chronic Obstructive Pulmonary Disease.
C Vivek Lal MD FAAP
Founder & CEO
Amit Gaggar MD PhD
Chief Medical Officer
Theodora Nicola MD PhD MBA
Lead Scientist
Yvonne Huang MD
Science Advisor, Microbiome and Adult Lung Disease
Nancy Wenger
Research and Development Manager
Nirmal Sharma MD
Science Advisor, Lung Transplant
Scientific Team
Alveolus Bio’s scientific team and advisors have expertise across a spectrum of chronic respiratory diseases from Bronchopulmonary Dysplasia, to Cystic Fibrosis, to Chronic Obstructive Pulmonary Disease.
Namasivayam Ambalavanan MD
Science Advisor, Pediatric Lung Disease
Casey Morrow PhD
Science Advisor, Microbiome
Mike Wells MD PhD
Science Advisor, Clinical Trials and Adult Lung Disease
Research Infrastructure
At the heart of Alveolus Bio is world class infrastructure and personnel to support in vivo and in vitro models of various respiratory diseases.
Alveolus Bio serves as a platform for respiratory drug development from discovery to clinical trials.
Publications
Neutrophilic inflammation during lung development disrupts elastin assembly and predisposes adult mice to COPD (2021)
Emerging evidence indicates that early life events can increase the risk for developing chronic obstructive pulmonary...
Early airway microbial metagenomic and metabolomic signatures are associated with development of severe bronchopulmonary dysplasia (2018)
The pathogenesis of bronchopulmonary dysplasia (BPD) is not well understood. We previously identified differences in...
The Airway Microbiome at Birth (2016)
Alterations of pulmonary microbiome have been recognized in multiple respiratory disorders. It is critically important...